Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
The advantages of both long-acting injections and oral administration of neuroleptic agents in treating schizophrenia are discussed. Problems related to patient noncompliance and other factors relevant in evaluating long-term maintenance therapy are considered, as well as variables that influence the duration of maintenance therapy. The results of discontinuation, whether initiated by patient or physician, are discussed, along with the limitations of long-term medication therapy (e.g., depression, dyskinesia, extrapyramidal symptoms). General guidelines are provided for evaluating dose requirements in maintenance therapy.
D000284:Administration, Oral; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D003866:Depressive Disorder / Q000209:etiology / Q000523:psychology; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D006801:Humans; D007273:Injections, Intramuscular; D010349:Patient Compliance; D012008:Recurrence; D012107:Research Design; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013997:Time Factors
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations